Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 1

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  clinical efficacy
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Content available remote

Selected classical and novel antiepileptic drugs – mechanisms of action, neuroprotection, and effectiveness in epileptic and non-epileptic conditions

100%
Chrościńska-Krawczyk M., Wałek M., Tylus B., Czuczwar S. J.
Journal of Epileptology
|
2014
|
vol. 22
|
issue 1
37-50
EN
Introduction. One of the most common neurological disorders is epilepsy, characterised by recurrent spontaneus seizures. Although not fully efficient in ca 30% of patients, pharmacologic treatment of epilepsy plays an important therapeutic approach not only against epilepsy. Aim. To provide data on the mechanism of action, activity and neuroprotective efficacy in experimental conditions, clinical efficacy against epilepsy and non-epileptic diseases of major, classical and newer antiepileptic drugs (AEDs – lamotrigine, topiramate, levetiracetam, valproate and carbamazepine). Methods. A literature search for publications written in English, preferably published within a period of the last fifteen years, using the key words listed below. Review. The majority of AEDs possess more than one mechanism of action. They exert their effect by acting on various receptors (different types of glutamatergic and mainly GABAA receptors), neurotransmitters (mainly glutamate or GABA) and voltage-gated ion channels (sodium or calcium ion channels). All reviewed AEDs possess neuroprotective activity, the weakest being carbamazepine. Apart from epilepsy, AEDs may be also used in the pharmacotherapy of migraine, neuropathic pain, spasticity, psychiatric disorders and Parkinsons's or Alzheimer's diseases. Conclusions. As highlighted above, around 30% of epileptic patients do not substantially benefit from AEDs. It is possible that rational combinations of AEDs, based upon experimental studies, could improve this outcome. The neuroprotective effects of AEDs may point to their disease-modifying activity.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.